Rural Community Hospital Demonstration Program Reauthorization
Summary
SB 4460, the Rural Community Hospital Demonstration Program Reauthorization, would extend the federal rural community hospital demonstration program from a 15-year extension period to a 20-year extension period. The bill amends section 410A of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to update the program’s duration and make conforming changes throughout the statute so the new 20-year timeline is reflected consistently.
The measure also adds a special rule for hospitals that were not original participants in the demonstration. During the fourth five years of the new 20-year extension period, the Secretary of Health and Human Services would apply certain provisions to qualifying rural community hospitals that participated in the program between December 30, 2024, and January 1, 2027, in the same manner as original participant hospitals. The bill was passed by the Senate on May 20, 2026, and was later held at the desk, indicating it had not completed the full legislative process at the time reflected in the context.
Impact
The bill would amend federal Medicare law, specifically section 410A of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, by lengthening the rural community hospital demonstration program and updating related statutory references. Its practical effect would be to keep the demonstration program available for an additional five years and to expand the timing framework under which certain non-original rural hospitals may receive comparable treatment under the program. The affected parties are rural community hospitals, the Secretary of Health and Human Services, and Medicare administration more broadly.
Sentiment
The available context suggests generally favorable treatment of the bill, as reflected by Senate passage and the absence of recorded committee opposition or vote data. The bill’s purpose is narrowly focused on continuing an existing rural hospital support program, which typically attracts support from lawmakers concerned about access to care in underserved areas. Because there are no committee transcripts or recorded votes in the provided context, there is little evidence of organized opposition in the available record.
Contention
No specific points of contention are documented in the provided materials. The only potentially debatable issue apparent from the text is the scope of the extension and the addition of a rule allowing some non-original participants to be treated similarly during the later years of the extension period. Any disagreement would likely center on program duration, eligibility, and whether the demonstration should be expanded or limited, but the context does not identify any members, committees, or stakeholders explicitly raising objections.
A bill for an act relating to controlled substances, including certain controlled substances schedules and precursor substances reporting requirements, making penalties applicable, and including effective date provisions. (Formerly HSB 25.) Effective date: 03/28/2025.
A bill for an act relating to controlled substances, including certain controlled substances schedules and precursor substances reporting requirements, making penalties applicable, and including effective date provisions.(See SF 305.)
A bill for an act relating to controlled substances, including certain controlled substances schedules and precursor substances reporting requirements, making penalties applicable, and including effective date provisions.(See HF 182.)